Results 231 to 240 of about 112,622 (301)

PARP inhibitor augments anti-tumor efficacy of DNMT inhibitor by inducing senescence in cholangiocarcinoma. [PDF]

Int J Biol Sci
Wang P, Xiao R, Chen J, Guan P, Heng HL, Liu L, Wang Y, Zeng X, Zhong G, Hao J, Gao J, Chan JY, Dima S, Ong CK, Teh BT, Li M, Hong JH, Tan J.   +17 more
europepmc   +1 more source

Harmine Derivatives as Anticancer Agents Endowed With Potent and Selective Antileukemia Activity: Synthesis, Biological Evaluation, Proapoptotic and Genotoxic Activity

Archiv der Pharmazie, Volume 359, Issue 2, February 2026.
We identified a novel N9‐substituted harmine analog, compound 6, that selectively suppresses leukemic cell growth, triggers DNA damage, and activates apoptosis while sparing healthy fibroblasts. This discovery highlights N9‐modified β‐carbolines as a powerful new class of selective antileukemic agents, bridging natural product chemistry with next ...
Abdul Aziz Timbilla, Filip Pidany, Eliska Kohelova, Jana Kroustkova, Karel Kralovec, Jan Rataj, Martina Ceckova, Negar Maafi, Víctor Lopez, Cristina Moliner Langa, Stefan Kosturko, Jaroslav Jenco, Darina Muthna, Darja Koutova, Martina Rezacova, Lucie Cahlikova, Jakub Chlebek, Radim Havelek   +17 more
wiley   +1 more source

Jab1 regulates HRR mRNA stability to modulate PARP inhibitor sensitivity in triple-negative breast cancer. [PDF]

Mol Cancer
Peng X, Wang Y, Yu Z, Huang S, Zhang S, Zhong Z, Wang Y, Liu S, Wang K, Nicot C, Claret FX, Kong D.   +11 more
europepmc   +1 more source

Statins in Breast Cancer Therapy: Mechanistic Insights and Emerging Evidence

Cancer Innovation, Volume 5, Issue 1, February 2026.
Statins, particularly simvastatin, demonstrate potential as adjuvant agents in breast cancer treatment by disrupting tumour cell signalling and survival pathways. This review highlights emerging evidence supporting their repurposing for improved outcomes, especially in aggressive breast cancer subtypes.
Rohina Alim, H. M. Kasuni Akalanka
wiley   +1 more source

Molecular mechanism of PARP inhibitor resistance. [PDF]

Oncoscience
Huang Y, Chen S, Yao N, Lin S, Zhang J, Xu C, Wu C, Chen G, Zhou D.   +8 more
europepmc   +1 more source

Potential Targets and Biomarkers of Radionuclide Therapy in Breast Cancer

Cancer Innovation, Volume 5, Issue 1, February 2026.
Potential biomarkers for the development of targeted radionuclide therapy that can be employed in the treatment of breast cancer have been summarised in the review. They include receptor markers of ER, PR and HER2, as well as other markers of Trop2, PD‐1, EGFR, GRPR and PSMA.
Yujing Tan, Cheng Zeng, Jiani Wang, Fei Ma   +3 more
wiley   +1 more source

Risk of myelodysplastic syndrome and acute myeloid leukemia related to PARP inhibitor maintenance line in real-world ovarian cancer patients. [PDF]

Oncologist
Farolfi A, Casadei C, Gentili N, Testoni S, Rusconi F, Giunta EF, Brighi N, Gurioli G, Montanari D, Ibarburu GH, De Giorgi U.   +10 more
europepmc   +1 more source

A Clinical Guidance for the Management of Patients With Hepatoid Adenocarcinoma and A Case Series

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Hepatoid adenocarcinoma (HAC) is a rare extrahepatic tumor of non‐germ cell origin that morphologically resembles hepatocellular carcinoma (HCC). HAC has a propensity to metastasize to the liver and therefore may be mistaken for HCC. There is a lack of standardized treatment protocols, and further studies are needed to evaluate the benefit of ...
Christina Liava, Sudhakar Venkatesh, Michael S. Torbenson, Patrick S. Kamath, Moira Hilscher   +4 more
wiley   +1 more source

Long non-coding RNAs as a biomarker for homologous recombination deficiency and parp inhibitor sensitivity in high-grade serous ovarian cancers. [PDF]

Commun Biol
Doberstein K, Panther J, Hahnen E, Richters L, Schouten PC, Harter P, Heitz F, Kommoss S, Berlit S, Tuschy B, Sütterlin M, Marmé F.   +11 more
europepmc   +1 more source

Prognosis of Metaplastic Breast Cancer: A Population‐Based Matched Cohort Study

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Purpose Metaplastic breast cancer (metBC) is a rare subtype of breast cancer known for its challenging management. The impact of this histological subtype on prognosis remains unclear. Methods Data were collected from the Swedish Cancer Registry between 2008 and 2018.
Marie Bergman, Aglaia Schiza, Ceren Boyaci, Balazs Acs, Alexios Matikas, Johan Hartman, Antonis Valachis   +6 more
wiley   +1 more source